<i>Neisseria meningitidis</i> is the most common cause of bacterial meningitis in children and young adults worldwide.A 4-component vaccine against <i>N. meningitidis</i> serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H binding protein (fHBP), neisserial heparin binding protein (NHBA), neisserial adhesin A (NadA), and PorA-containing outer membrane vesicles was recently approved for use in the United States and other countries worldwide.